同方康泰(01312.HK)附屬與延安必康訂框架協議 就藥品研發製造及銷售進行合作
同方康泰(01312.HK)公布,全資附屬同方藥業與延安必康(002411.SZ)訂立合作框架協議,雙方將就藥品的研發、製造及銷售方面進行深度合作,共同探索及拓展中國境內外的醫藥市場。雙方將進一步商討具體的合作範疇,並可能在適當時訂立相關合作協議。
延安必康致力於研發、生產、銷售現代中藥及化學藥品,用於治療循環系統、消化系統、呼吸系統、神經系統以及眼科和兒科疾病等。
集團指,根據框架協議擬進行的與延安必康的合作,可有效提升集團產能利用率,優化產品組合,提升商業渠道的銷售能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.